80 CENTS PRICE TARGET, page-103

A quick scan on the market Cap of some of the ASX Biotech companies that are in phase 2 trials:
PAA ( Now NUZ) – $69M
SNT - $106M
ILA - $48M

Late stage Phase 2:
PAR - $117M
OIL - $111M
RCE - $85M

Phase 3 Companies:
DXB - $334M
NEU - $1.74B
TLX – $8.99B
OPT - $739M

Knowing that not all of the above are comparable, but this is just to show that our current market Cap of $8.5M has a lot of headroom to move once we start our phase 2 trials.

Given the possibility of us able to bypass phase 3 trials, that $100M market cap hurdle that you've mentioned could be easily crossed once we have a favorable indication by the late stage of phase 2.

Congratulations to all holders.